Bivalent bispecific antibody hybrid protein expression and preparation methods

Patent metadata

Field	Value
Publication number	US-11535674-B2
Application number	US-201616079003-A
Country	US
Kind code	B2
Filing date	Dec 16, 2016
Priority date	Feb 23, 2016
Publication date	Dec 27, 2022
Grant date	Dec 27, 2022

Abstract

The present disclosure discloses a method for expressing and preparing a bivalent bispecific antibody. In the present disclosure, each portion of a bivalent bispecific antibody and an immune hybrid protein thereof is respectively expressed in a suitable prokaryotic or eukaryotic cell system, separated and purified by high-performance affinity chromatography, and then spliced in vitro by trans-splicing reaction mediated by an intein, to prepare the bivalent specific antibody and an immune hybrid protein thereof.

First claim

What is claimed is:

1. A method for expressing and preparing a bivalent bispecific antibody, the bivalent bispecific antibody comprising a first light chain and a first heavy chain of an antibody that specifically binds to a first antigen, and a second light chain and a second heavy chain of an antibody that specifically binds to a second antigen, the method comprising:
S1: providing a first polynucleotide sequence and a second polynucleotide sequence, wherein the first polynucleotide sequence encodes a portion A antibody,
wherein the second polynucleotide sequence encodes a portion B antibody, wherein the portion A antibody comprises the first light chain, the first heavy chain, an Fc chain of the second heavy chain, a part A of a hinge of the second heavy chain linked to the N-terminus of the Fc chain of the second heavy chain and a C-terminal fragment of a split intein (Ic) fused to the N terminus of then part A of the hinge of the second heavy chain, wherein the portion B antibody comprises the second light chain a VH+CH1 chain of the second heavy chain, a part B of the hinge of the second heavy chain linked to the C-terminus of the VH+CH1 chain of the second heavy chain, and a N-terminal fragment of the split intein (In) fused to the C terminus of the part B of the hinge of the second heavy chain, and
S2: constructing a first mammalian cell expression vector and a second mammalian cell expression vector, wherein the first mammalian cell expression vector comprises the first polynucleotide sequence and is configured to express the portion A antibody, and the second mammalian cell expression vector comprises the second polynucleotide sequence and is configured to express the portion B antibody;
S3: transfecting a first mammalian cell with the first mammalian expression vector, and inducing the first mammalian cell transfected with the first mammalian cell expression vector to express the portion A antibody; and transfecting a second mammalian cell with the second mammalian expression vector, and inducing the second mammalian cell transfected with the second mammalian cell expression vector to express the portion B antibody; and
S4: purifying the expressed portion A antibody and the expressed portion B antibody respectively, and subjecting the Ic of the portion A antibody and the In of the portion B antibody to trans-splicing in vitro, to obtain the bivalent bispecific antibody,
wherein
the trans-splicing, in vitro, occurs at a temperature of 4-37° C., is continued for 5-20 min, and the concentration of the sulfhydryl compound is 0.05-2 mM and the split intein is Npu DNA E or Ssp DnaE,
wherein the Fc chain of the second heavy chain in portion A antibody is fused to the VH+CH1 chain of the second heavy chain in portion B antibody by the Ic/In linkage of the part A of the hinge and the part B of the hinge of the second heavy chain, and
wherein the part A of hinge is one portion of the hinge region of the antibody, the part B of hinge is another portion of said hinge region of the antibody, and part A and part B are fused to a whole of said hinge region after trans-splicing of the intein in S4.

2. The method for expressing and preparing a bivalent bispecific antibody according to claim 1 , wherein the bivalent bispecific antibody comprises a knob-in-hole structure with a knob formed at a CH3 domain in the first heavy chain and a hole formed at a CH3 domain in the second heavy chain.

3. The method for expressing and preparing a bivalent bispecific antibody according to claim 2 , wherein the threonine at position 366 in the CH3 domain of the first heavy chain is mutated to tryptophan to form the knob; and in the CH3 domain of the second heavy chain, the threonine at position 366 is mutated to serine, the leucine at position 368 is mutated to alanine, and the tyrosine at position 407 is mutated to valine, to form the hole.

4. The method for expressing and preparing a bivalent bispecific antibody according to claim 3 , wherein the serine at position 354 in the CH3 domain of the first heavy chain is mutated to cysteine; and the tyrosine at position 349 in the CH3 domain of the second heavy chain is mutated to cysteine.

5. The method for expressing and preparing a bivalent bispecific antibody according to claim 1 , wherein the bivalent bispecific antibody comprises a knob-in-hole structure with a hole formed at a CH3 domain in the first heavy chain and a knob formed at a CH3 domain in the second heavy chain.

6. The method for expressing and preparing a bivalent bispecific antibody according to claim 5 , wherein in the CH3 domain of the first heavy chain, the threonine at position 366 is mutated to serine, the leucine at position 368 is mutated to alanine, and the tyrosine at position 407 is mutated to valine, to form the hole; and wherein in the CH3 domain of the second heavy chain, the threonine at position 366 is mutated to tryptophan, to form the knob.

7. The method for expressing and preparing a bivalent bispecific antibody according to claim 6 , wherein in the CH3 domain of the first heavy chain, the tyrosine at position 349 is mutated to cysteine; and in the CH3 domain of the second heavy chain, the serine at position 354 is mutated to cysteine.

8. The method for expressing and preparing a bivalent bispecific antibody according to claim 1 , wherein the transfection of mammalian cells is transient transfection of 293-E, 293-F or CHO cells, or stable transfection of CHO cells.

9. The method for expressing and preparing a bivalent bispecific antibody according to claim 1 , further comprising: terminating the trans-splicing reaction and purifying the product obtained after trans-splicing, in vitro, to obtain the bivalent bispecific antibody.

10. The method for expressing and preparing a bivalent bispecific antibody according to claim 1 , wherein the sulfhydryl compound comprises DTT, β-mercaptoethanol and/or TCEP.

Assignees

• Univ Shanghai Jiaotong
• Jecho Laboratories Inc
• Jecho Biopharmaceuticals Co Ltd

Inventors

• Han Lei
• Zhu Jianwei
• Chen Junsheng
• Ding Kai
• Xie Yueqing
• Jiang Hua
• Lu Huili
• Zhang Baohong
• Zhang Lei

Classifications

• C12N15/62

  DNA sequences coding for fusion proteins · CPC title

• C07K16/46 Primary

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title

• C07K16/468 Primary

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K2317/524

  CH2 domain · CPC title